AI Tool Diagnoses Advanced Heart Failure with High Accuracy

Revolutionizing Advanced Heart Failure Diagnosis with AI

Advanced heart failure, a debilitating condition affecting hundreds of thousands globally, has long presented a significant diagnostic challenge. Patients often suffer from delayed diagnosis due to the complex and resource-intensive nature of current assessment methods. However, a groundbreaking study from a collaborative team at Weill Cornell Medicine, Cornell Tech, Cornell Ann S. Bowers College of Computing and Information Science, Columbia University Vagelos College of Physicians and Surgeons, and NewYork-Presbyterian is set to change this landscape. Researchers have successfully developed and tested an artificial intelligence (AI) powered tool that can identify patients with advanced heart failure with high accuracy using routine cardiac ultrasound data and electronic health records (EHRs). This innovative approach promises to democratize diagnosis and significantly improve patient care.

The Diagnostic Bottleneck: Why AI is Critical

Currently, the definitive diagnosis of advanced heart failure relies heavily on cardiopulmonary exercise testing (CPET). While effective, CPET is a specialized procedure demanding expensive equipment and highly trained personnel, making it primarily available only at large academic medical centers. This creates a substantial diagnostic bottleneck, leading to an estimated 200,000 Americans with advanced heart failure being underserved or undiagnosed each year. The lack of widespread access to CPET means that many patients miss the window for timely interventions and specialized care.

The new AI-powered method directly tackles this issue by providing a more accessible and scalable diagnostic solution. "This opens up a promising pathway for more efficient assessment of patients with advanced heart failure using data sources that are already embedded in routine care," explains Dr. Fei Wang, associate dean for AI and data science and the Frances and John L. Loeb Professor of Medical Informatics at Weill Cornell Medicine, and senior author of the study. By predicting peak oxygen consumption (peak VO2)—the most critical CPET measure—from easily obtainable ultrasound images and EHR data, the AI model bypasses the traditional constraints, ensuring more patients can be identified and receive appropriate care.

The AI tool's remarkable capability stems from its sophisticated multi-modal, multi-instance machine learning model. Developed by Dr. Wang's team, including lead authors Dr. Zhe Huang and Dr. Weishen Pan, this model can process several distinct types of data simultaneously, offering a comprehensive view of a patient's cardiac health.

Data Type	Description	Role in AI Model
Ordinary Moving Ultrasound	Dynamic images showing heart structure and function	Visual cues for cardiac contractility, chamber sizes, and wall motion
Waveform Imagery	Graphical representations of heart valve dynamics and blood flow patterns	Insights into blood flow anomalies and valve functionality
Electronic Health Records	Patient demographics, medical history, lab results, medications, etc.	Contextual information for a holistic patient profile

This ability to fuse and interpret diverse data streams allows the AI to learn complex patterns indicative of advanced heart failure that might be missed through isolated data analysis. The model was rigorously trained using deidentified data from 1,000 heart failure patients at NewYork-Presbyterian/Columbia University Irving Medical Center. Post-training, its performance was validated on a new cohort of 127 heart failure patients from three other NewYork-Presbyterian campuses. The results were compelling, demonstrating an overall accuracy of roughly 85% in distinguishing high-risk patients. This high accuracy suggests its potential utility in real-world clinical settings, offering a new benchmark for evaluating AI agents for production in medical diagnostics.

Promising Results and Collaborative Innovation

The success of this AI tool is a testament to the power of interdisciplinary collaboration, a hallmark of the Cardiovascular AI Initiative, a broader effort by Cornell, Columbia, and NewYork-Presbyterian. Dr. Nir Uriel, director of advanced heart failure and cardiac transplantation at NewYork-Presbyterian, played a pivotal role in initiating the project. "Initially we put together a group of more than 40 heart failure specialists and asked them to tell us where they thought AI could best be applied," he recounted. This clinician-led approach ensured that the AI solution directly addressed a critical clinical need.

Dr. Deborah Estrin, associate dean for impact at Cornell Tech, emphasized the symbiotic relationship: "The close interaction between clinicians and AI researchers on this project ended up driving the development of new AI techniques that would not have been explored otherwise. So, this was a case of medicine shaping the future of AI—not just AI shaping the future of medicine." This collaborative spirit, bridging clinical expertise with cutting-edge AI research, was crucial to developing a robust and clinically relevant tool. Such partnerships are essential for advancing AI applications in sensitive domains like healthcare, where data privacy and ethical considerations are paramount. Efforts around enterprise privacy in handling medical data are continuously evolving.

Paving the Way for Clinical Integration and Future Impact

The promising results from this study mark a significant step towards integrating AI into routine cardiovascular care. The research team is already planning clinical studies, a necessary phase for obtaining U.S. Food and Drug Administration (FDA) approval and subsequent widespread clinical adoption. Dr. Uriel underscored the transformative potential: "If we can use this approach to identify many advanced heart failure patients who would not be identified otherwise, then this will change our clinical practice and significantly improve patient outcomes and quality of life."

This AI tool represents more than just a technological advancement; it's a paradigm shift in how advanced heart failure could be diagnosed, making precision medicine more accessible. By leveraging existing infrastructure (ultrasound machines) and widely available data (EHRs), the model reduces the barriers to early detection, ensuring more patients receive timely, life-saving treatments. The success of this initiative will undoubtedly inspire further exploration into AI's role in various medical specialties, ultimately enhancing diagnostic accuracy and patient care across the board.

Original source

https://news.weill.cornell.edu/news/2026/03/ai-tool-shows-promise-in-diagnosing-advanced-heart-failure

Frequently Asked Questions

What is advanced heart failure and why is its diagnosis challenging?

Advanced heart failure is a severe, chronic condition where the heart struggles to pump enough blood to meet the body's needs, significantly impacting quality of life and prognosis. Diagnosing this condition accurately is critically challenging due to its complex nature and the limitations of current standard diagnostic procedures. The gold standard, cardiopulmonary exercise testing (CPET), requires specialized equipment and highly trained personnel, making it accessible only in large, tertiary medical centers. This bottleneck means that a vast number of patients who could benefit from advanced therapies are often overlooked or diagnosed late, delaying crucial interventions and worsening outcomes. The difficulty in early and widespread detection underscores the urgent need for more accessible and efficient diagnostic methods, which this new AI tool aims to provide by simplifying the diagnostic pathway and democratizing access to timely identification of the condition.

How does the new AI tool specifically improve upon existing diagnostic methods like CPET?

The AI tool developed by Weill Cornell Medicine and its partners represents a significant leap forward by overcoming the inherent limitations of CPET. Unlike CPET, which demands specialized facilities and staff, the AI model utilizes readily available cardiac ultrasound images and electronic health records (EHRs)—data sources routinely collected in most clinical settings. By processing these common data types, the AI can predict peak oxygen consumption (peak VO2), the most crucial measure derived from CPET, with high accuracy. This dramatically reduces the need for expensive, time-consuming, and resource-intensive CPETs. The improvement lies in its scalability and accessibility; it transforms a complex diagnostic process into one that can be integrated into routine clinical care, potentially identifying tens of thousands more patients who would otherwise go undiagnosed due to geographical or resource constraints.

What types of data does the AI model leverage for its predictions?

The innovative AI model is a multi-modal, multi-instance machine learning system, designed to synthesize information from diverse clinical data sources for a comprehensive assessment. It specifically processes three distinct categories of data. Firstly, it analyzes ordinary moving ultrasound images of the heart, capturing critical visual information about cardiac structure and function. Secondly, it incorporates related waveform imagery, which displays intricate details of heart valve dynamics and blood flow patterns. Lastly, the model integrates various items found in the patient’s electronic health records (EHRs), including demographic information, medical history, lab results, and other clinical parameters. The ability to combine and interpret these disparate data types allows the AI to develop a holistic understanding of a patient's cardiac health, leading to more accurate predictions.

What was the accuracy of the AI model in predicting peak VO2, and what does this mean clinically?

The AI model achieved a remarkable overall accuracy of roughly 85% in predicting peak VO2, which is a significant indicator for distinguishing high-risk patients with advanced heart failure. This figure was measured using a metric that assesses the probability of a randomly chosen high-risk patient having a higher predicted risk than a randomly chosen lower-risk patient. Clinically, an 85% accuracy suggests that the tool is highly effective and reliable in identifying individuals who require advanced heart failure care. This level of precision means that the AI can act as a powerful screening or supplementary diagnostic tool, helping clinicians more confidently and quickly identify patients who would benefit most from further evaluation or specialized treatments. This promising result paves the way for potential FDA approval and widespread adoption in healthcare.

Which institutions and key individuals collaborated on the development of this AI tool?

This groundbreaking study was the result of a highly collaborative effort involving several leading institutions and prominent experts. Key collaborating entities included Weill Cornell Medicine, Cornell Tech, Cornell Ann S. Bowers College of Computing and Information Science, Columbia University Vagelos College of Physicians and Surgeons, and NewYork-Presbyterian. The study was senior-authored by Dr. Fei Wang, Associate Dean for AI and Data Science at Weill Cornell Medicine. Other pivotal contributors included Dr. Deborah Estrin, Associate Dean for Impact at Cornell Tech, and Dr. Nir Uriel, Director of Advanced Heart Failure and Cardiac Transplantation at NewYork-Presbyterian. The AI team, under Dr. Wang, also included lead authors Dr. Zhe Huang and Dr. Weishen Pan, along with students and faculty from Cornell Bowers, highlighting a robust interdisciplinary approach to medical innovation.

What are the next steps for bringing this AI diagnostic tool into routine clinical practice?

The research team is actively planning the crucial next steps required to transition this promising AI diagnostic tool from a research finding to routine clinical practice. The immediate focus will be on conducting extensive clinical studies. These studies are essential to further validate the model's performance in diverse patient populations and real-world clinical settings, gathering the robust evidence necessary for regulatory approvals. Achieving U.S. Food and Drug Administration (FDA) approval is a critical milestone for widespread adoption. Following approval, efforts will concentrate on integrating the AI tool seamlessly into existing healthcare workflows and electronic health record systems. The ultimate goal is to enable clinicians to easily leverage this technology, ensuring more patients with advanced heart failure are identified and receive appropriate care in a timely manner, transforming current diagnostic paradigms.

How does this research embody the intersection of medicine and AI innovation?

This research project serves as a prime example of how the synergy between medicine and AI innovation can drive transformative advancements in healthcare. It began with clinicians, specifically heart failure specialists, identifying a critical unmet need—the diagnostic bottleneck for advanced heart failure. This clinical challenge then inspired AI experts to develop novel machine learning techniques, demonstrating a unique 'medicine shaping AI' dynamic. The multi-modal AI model, capable of interpreting complex medical images and electronic health records, showcases AI's potential to extract subtle, actionable insights that might elude human analysis or standard tests. This interdisciplinary approach not only addresses a significant clinical problem but also pushes the boundaries of AI research, developing models specifically tailored for the intricacies of medical data and clinical decision-making. It highlights the power of collaborative innovation in solving real-world healthcare issues.

What are the broader implications of this AI tool for patient care and healthcare systems?

The broader implications of this AI diagnostic tool for patient care and healthcare systems are profound. Firstly, it promises to significantly improve patient outcomes and quality of life by enabling earlier and more accurate identification of advanced heart failure. This means patients can receive timely interventions, advanced therapies, or even transplantation referrals, preventing disease progression and reducing mortality. Secondly, it addresses health disparities by making advanced diagnostic capabilities accessible beyond specialized centers, potentially reaching underserved populations. For healthcare systems, the tool could lead to more efficient resource allocation, reducing the burden on CPET facilities and streamlining diagnostic pathways. It also sets a precedent for how AI can be integrated into routine care to augment clinical decision-making, offering a scalable solution to complex medical challenges and enhancing the overall precision and accessibility of cardiovascular medicine.

Stay Updated

Get the latest AI news delivered to your inbox.